Recombinant Escherichia coli for synthesizing 2′-fucosyllactose using mannose and its application
By reconstructing the metabolic pathway of E. coli through gene editing, 2′-fucosylated lactose was synthesized using mannose as a carbon source, solving the problem of low conversion rate in existing biosynthetic methods and realizing efficient industrial production.
Patent Information
- Application Number
- CN202210018189.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-01-07
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-01-07
AI Technical Summary
Among existing biosynthetic methods, the conversion rate of 2′-fucosylated lactose is low, making it difficult to meet the needs of industrial production. In particular, the synthesis route using mannose as a carbon source is not very efficient.
The metabolic pathway of E. coli was reconstructed using gene editing technology. The gene manA encoding mannose phosphate isomerase was knocked out, and genes such as mannose phosphate isomerase and α-(1,2)-fucosyltransferase were overexpressed. 2′-fucosyl lactose was synthesized using mannose as a carbon source, thus separating the growth and production process of E. coli.
It significantly improved the conversion rate of mannose as a carbon source for the synthesis of 2′-fucosylated lactose, realizing efficient fermentation production of Escherichia coli and improving carbon source utilization.
Smart Images

Figure CN114276971B_ABST
Abstract
Description
Technical field:
[0001] The invention relates to a method for constructing a 2'-fucosyllactose-producing recombinant Escherichia coli. The strain has improved mannose utilization efficiency and belongs to the field of microbial metabolic engineering. Background technology:
[0002] Human milk oligosaccharides (HMOs) are a unique class of carbohydrates naturally present in breast milk that have many benefits for human health. Currently, people focus on their application as food additives.
[0003] 2′-fucosyllactose (2′-FL) is the largest human milk oligosaccharide (HMO) product (accounting for about 31%). It can be used by beneficial microbial flora in the intestines to regulate intestinal microorganisms. Adding 2′-FL to infant formula can enhance the immunity of newborn babies and effectively enhance the physical fitness of newborn babies. 2′-FL also plays a role in brain development, neuronal transmission and synapse formation, so adding 2′-FL to the diet can promote brain development and improve learning and memory abilities. At present, 2′-FL is mainly used in the production of infant formula, functional foods and beverages, and can also be used as a food additive, so the direct synthesis of 2′-FL has good prospects.
[0004] At present, the methods for synthesizing 2′-FL mainly include chemical synthesis and biosynthesis. Chemical synthesis requires repeated and multiple protection and deprotection of 2′-FL, and the process is very cumbersome, which will reduce the yield and increase the cost. The use of microorganisms to synthesize 2′-FL is currently a feasible method for large-scale production of 2′-FL. Compared with chemical synthesis methods, biosynthesis methods are safer and faster, and a large amount of toxic reagents do not need to be introduced during the synthesis process, which greatly increases the safety of the product. However, the culture medium for 2′-FL synthesized by biosynthesis currently mainly uses glycerol or glucose as a carbon source to convert it into GDP-fucose, and the conversion rate for synthesizing 2′-FL is generally not high. At present, there are two main metabolic pathways for microbial production of 2′-fucosyllactose, namely the de novo synthesis pathway and the salvage pathway ( Figure 1). The de novo synthesis pathway mainly starts from the intracellular metabolite fructose-6-phosphate, and synthesizes GDP-fucose through the sequential action of manA (phosphomannose isomerase), manB (phosphomannose mutase), manC (mannose-1-phosphate guanyl transferase), gmd (GDP-mannose-6-dehydrogenase) and wcaG (GDP-fucose synthase), and further synthesizes 2′-fucosyllactose through the action of futC (α-(1,2)-fucosyltransferase) with GDP-fucose and lactose as substrates. The salvage pathway converts fucose into GDP-fucose through the action of fucose 1-kinase / GDP-fucose pyrophosphorylase (Fkp), and further synthesizes 2′-fucosyllactose through the action of futC (α-(1,2)-fucosyltransferase) with GDP-fucose and lactose as substrates.
[0005] The salvage pathway requires fucose as a carbon source to produce 2′-fucosyllactose. Due to the high cost of using fucose as a carbon source, it basically has no potential for industrial production. The de novo synthesis pathway of 2′-fucosyllactose can use glycerol or glucose as a carbon source to synthesize GDP-fucose and then synthesize 2′-fucosyllactose, which has the possibility of industrial production. However, since the 2′-fucosyllactose synthesis pathway is weak and difficult to compete with the glycolysis pathway, a large amount of carbon source is consumed by cell growth or metabolism, and the carbon source utilization rate for the production of 2′-fucosyllactose is low, resulting in a low level of 2′-fucosyllactose production.
[0006] The present application provides a method for producing GDP-fucose and 2′-FL by using mannose as a carbon source. Summary of the invention:
[0007] In order to solve the above technical problems, the present invention uses gene editing technology to reconstruct the metabolic pathway of Escherichia coli to synthesize 2′-fucosyllactose and knock out the phosphomannose isomerase encoding gene manA, so that Escherichia coli uses carbon sources such as glucose or glycerol to enter the EMP pathway (glycolysis pathway) for growth metabolism. Due to the lack of manA gene, glycerol or glucose in the culture medium cannot enter the de novo synthesis pathway of synthesizing 2′-fucosyllactose in Escherichia coli to synthesize 2′-fucosyllactose; at the same time, due to the lack of manA gene, mannose cannot be used by Escherichia coli to enter the growth metabolic pathway when entering Escherichia coli. Therefore, the modified Escherichia coli uses carbon sources such as glucose or glycerol for growth metabolism, uses mannose entering the cell as a carbon source to enter the de novo synthesis pathway of 2′-fucosyllactose to synthesize GDP-fucose, and then synthesizes 2′-fucosyllactose, thereby improving the efficiency of Escherichia coli in utilizing carbon sources in the culture medium.
[0008] One of the technical solutions provided by the present invention is a genetically engineered bacterium that can utilize carbon sources such as glucose or glycerol for growth metabolism and utilize mannose as a carbon source to synthesize 2′-fucosyllactose. The engineered bacterium uses Escherichia coli as a starting strain, firstly knocks out P in the lac operon sequence, lac Promoter sequence and lacI, lacZ genes, and use P at the lacI, lacZ gene sites trc The promoter overexpressed the wcaG, gmd, and lacy genes, and then the phosphomannose isomerase encoding gene manA was knocked out in the genome, and the phosphomannose mutase encoding gene manB, the α-(1,2)-fucosyltransferase encoding gene futC, and the mannose-1-phosphate guanyltransferase encoding gene manC were expressed using plasmids;
[0009] Furthermore, the UDP-glucose lipid carrier transferase encoding gene Wcaj was knocked out;
[0010] Furthermore, the starting strain is Escherichia coli MG1655;
[0011] Furthermore, the P lac Promoter, the nucleotide sequence of which is shown in SEQ ID NO: 1;
[0012] Furthermore, the lacI gene has a nucleotide sequence as shown in SEQ ID NO: 2 in the sequence listing;
[0013] Furthermore, the lacZ gene, the nucleotide sequence is shown in the sequence listing SEQ ID NO: 3;
[0014] Furthermore, the P trc Promoter, the nucleotide sequence of which is shown in SEQ ID NO:4;
[0015] Furthermore, the nucleotide sequence of wcaG is shown in the sequence listing SEQ ID NO:5;
[0016] Furthermore, the nucleotide sequence of gmd is shown in the sequence listing SEQ ID NO:6;
[0017] Furthermore, the nucleotide sequence of the lacy gene is shown in the sequence listing SEQ ID NO:7;
[0018] Furthermore, the nucleotide sequence of manA is shown in the sequence listing SEQ ID NO:8;
[0019] Furthermore, the nucleotide sequence of manB is shown in the sequence listing SEQ ID NO:9;
[0020] Furthermore, the nucleotide sequence of futC is shown in the sequence listing SEQ ID NO: 10;
[0021] Furthermore, the nucleotide sequence of manC is shown in the sequence listing SEQ ID NO: 11;
[0022] Furthermore, the nucleotide sequence of Wcaj is shown in the sequence listing SEQ ID NO: 12;
[0023] Furthermore, pSB4K5 plasmid was used to express futC and manC;
[0024] Furthermore, pTrc99a plasmid was used to express manb.
[0025] The second technical solution provided by the present invention is the application of the genetically engineered bacteria described in the first technical solution, especially the application in synthesizing 2′-fucosyllactose using mannose as a carbon source. Specifically, the method for producing 2′-fucosyllactose is as follows:
[0026] The engineered bacteria seed solution was inoculated into the fermentation medium at a rate of 2-10%, and ampicillin and kanamycin (final concentration 50 μg / mL) were added, and the culture was carried out at 30-37°C, 400-600rpm, and cultured for 36-52h;
[0027] The fermentation medium is composed of: 1.5-3.5 g / L KH2PO4, 1.5-3.5 g / L NH4Cl, 1.7-2.5 g / L citric acid, 1.4-2 g / L MgSO4·7H2O, 5-7 g / L yeast powder, 10-20 mL / L trace element solution, 1-10 g / L mannose, 10-15 g / L glycerol, 5-10 g / L lactose, and the rest is water; the pH is adjusted to about 7.0;
[0028] Furthermore, the trace element solution composition is as follows: 10 g / L FeSO4·7H2O, 2.2 g / L ZnSO·7H2O, 1.0 g / L CuSO4·5H2O, 0.38 g / L MnSO4·H2O, 0.02 g / L Na2B4O7·10H2O, 0.1 g / L (NH4)6Mo7O 24 , 2.0g / L CaCl2, the rest is water;
[0029] After 36-52 hours of fermentation, the fermentation liquid was collected and the cells were broken to detect the content of 2′-fucosyllactose, which reached 0.23-4.95 g / L, and the utilization of mannose reached 10.77%-96.2%;
[0030] Preferably, 2g / L KH2PO4, 2g / L NH4Cl, 1.7g / L citric acid, 1.4g / LMgSO4·7H2O, 5g / L yeast powder, 10mL / L trace element solution, 5g / L mannose, 10g / L glycerol, 5g / L lactose are added to the fermentation medium, and the rest is water; the pH is adjusted to about 7.0; after 48h of fermentation, the content of 2′-fucosyllactose is 4.19g / L, and the utilization of mannose reaches 58.69%±1.48%, and the effect is optimal.
[0031] Beneficial effects:
[0032] The present invention provides a fermentation strategy for producing 2′-fucosyllactose by a de novo synthesis pathway of 2′-fucosyllactose. In a manA-knocked strain, due to the lack of the manA gene, glycerol in the culture medium cannot enter Escherichia coli to synthesize 2′-fucosyllactose by a de novo synthesis pathway. At the same time, due to the lack of the manA gene, mannose entering the Escherichia coli cannot be utilized to enter the growth metabolic pathway, so the mannose entering the cell is used as a carbon source to enter the 2′-fucosyllactose. The synthetic pathway synthesizes GDP-fucose and then synthesizes 2′-fucosyllactose, achieving the technical effect of separating the growth of Escherichia coli and the production of 2′-FL, increasing the conversion rate of mannose to synthesize GDP-fucose and then produce 2′-fucosyllactose, knocking out the Wcaj gene allows Escherichia coli to use mannose to synthesize GDP-fucose, and further improves the conversion rate of producing 2′-fucosyllactose. This strategy can greatly improve the carbon source utilization rate of Escherichia coli fermentation to produce 2′-fucosyllactose. Description of the drawings:
[0033] Figure 1 De novo and salvage pathways for the production of 2′-fucosyllactose
[0034] Gapa: 3-phosphate glyceraldehyde dehydrogenase; fbaA: fructose bisphosphate aldolase; pfkA / pfkB: 6-phosphofructokinase; manA: mannose isomerase; manB: phosphomannose mutase; manC: mannose-1-phosphate guanylyltransferase; gmd: GDP-mannose-4,6-dehydratase; wcaG: GDP-fucose synthase; Fkp: fucose 1-kinase / GDP-fucose pyrophosphorylase; futC: α-(1,2)-fucosyltransferase; setA: sugar efflux transporter; lacZ: β-galactosidase; lacy: lactose permease; Wcaj: UDP-glucose lipid carrier transferase.
[0035] Figure 2 Colony PCR verification of strain L
[0036] Lane M-marker; Lane 1-strain L;
[0037] Verification length 3305bp; verification primers: mhpr-up / lacy-down.
[0038] Figure 3 Colony PCR verification of strain L1
[0039] Lane M-marker; Lane 1-strain L1;
[0040] Verification length: 1863bp;
[0041] Validation primer: CS-YZ-F: ttggcagttcatcatagtatttcg
[0042] manA-down-R:cgtcattgaccagatccga.
[0043] Figure 4 Colony PCR verification of strain L2
[0044] Lane M-marker; Lane 1-strain L2;
[0045] Verification length: 1290bp;
[0046] Validation primers: W-YZ-F: GCCGCTTTGTTAACGAAACC
[0047] W-YZ-R:GCCCGATCAGCGGAGATACC.
[0048] Figure 5 Colony PCR verification of strain L3
[0049] Lane M-marker; Lane 1-strain L3; Lane 2-strain L3;
[0050] Verified length: 3427bp (verified by transformation into pTrc99a-manb-mana plasmid)
[0051] Validation primer: 99a-yz-f:gcgcaacgcaattaatgtg
[0052] 99a-AB-tet-r:agcgcattgttagatttcatactcttcctttttcaatattattgaagcat
[0053] Verified length: 3186 bp (converted into pSB4K5-futC-manC plasmid)
[0054] Validation primer: pSB4K5YZ-F:cagaattggttaattggttggtgc
[0055] psb4k5-futc-R: gccgaggtgagaagggttcccatggattcttcgtctgt.
[0056] Figure 6 Colony PCR verification of strain L4 (verification of transformation into pTrc99a-manb plasmid)
[0057] Lane M-marker; Lane 1-strain L4;
[0058] Verification length: 2175bp
[0059] Validation primer: 99a-yz-f:gcgcaacgcaattaatgtg
[0060] 99a-AB-tet-r:agcgcattgttagatttcatactcttcctttttcaatattattgaagcat
[0061] Figure 7 Colony PCR verification of strain L4 (verification of transformation into pSB4K5-futC-manC plasmid)
[0062] Lane M-marker; Lane 1-strain L4;
[0063] Verification length: 3186bp
[0064] Validation primer: pSB4K5YZ-F:cagaattggttaattggttggtgc
[0065] psb4k5-futc-R: gccgaggtgagaagggttcccatggattcttcgtctgt.
[0066] Figure 8 Colony PCR verification of strain L5
[0067] Lane M-marker; Lane 1-strain L5; Lane 2-strain L5;
[0068] Verified length: 3186 bp (converted into pSB4K5-futC-manC plasmid)
[0069] Validation primer: pSB4K5YZ-F:cagaattggttaattggttggtgc
[0070] psb4k5-futc-R: gccgaggtgagaagggttcccatggattcttcgtctgt.
[0071] Verified length: 3427bp (verified by transformation into pTrc99a-manb-mana plasmid)
[0072] Validation primer: 99a-yz-f:gcgcaacgcaattaatgtg
[0073] 99a-AB-tet-r:agcgcattgttagatttcatactcttcctttttcaatattattgaagcat
[0074] Figure 9 Colony PCR verification of strain L6 (verification of transformation into pTrc99a-manb plasmid)
[0075] Lane M-marker; Lane 1-strain L6;
[0076] Verification length: 2175bp
[0077] Validation primer: 99a-yz-f:gcgcaacgcaattaatgtg
[0078] 99a-AB-tet-r:agcgcattgttagatttcatactcttcctttttcaatattattgaagcat
[0079] Figure 10 Colony PCR verification of strain L6 (verification of transformation into pSB4K5-futC-manC plasmid)
[0080] Lane M-marker; Lane 1-strain L6;
[0081] Verification length: 3186bp
[0082] Validation primer: pSB4K5YZ-F:cagaattggttaattggttggtgc
[0083] psb4k5-futc-R: gccgaggtgagaagggttcccatggattcttcgtctgt. Specific implementation method:
[0084] The present invention is described below by specific embodiments. Unless otherwise specified, the technical means used in the present invention are methods known to those skilled in the art. In addition, the embodiments should be understood as illustrative rather than limiting the scope of the present invention, and the essence and scope of the present invention are limited only by the claims. For those skilled in the art, various changes or modifications to the material composition and dosage in these embodiments, without departing from the essence and scope of the present invention, also belong to the protection scope of the present invention.
[0085] After the Escherichia coli is modified, the present invention enables it to use different carbon sources for growth metabolism and production of 2'-fucosyllactose respectively. The addition of mannose in the culture medium increases the conversion rate of mannose into GDP-fucose in Escherichia coli, and then produces 2'-fucosyllactose. Using Escherichia coli MG1655 as the original strain, the P in the lac operon sequence is knocked out. lac Promoter sequence and lacI, lacZ genes, and use P at the lacI, lacZ gene sites trc The promoter overexpressed wcaG, gmd, and lacy genes as the chassis strain, and the gene editing technology was used to knock out the phosphomannose isomerase (manA) gene in the genome, so that mannose did not enter the glycolysis (EMP) pathway, avoiding mannose being metabolized and utilized by E. coli for growth. On this basis, the UDP-glucose lipid carrier transferase (Wcaj) gene was further knocked out, so that GDP-fucose synthesized from mannose did not enter the colanic acid (CA) synthesis pathway, thereby improving the utilization of mannose in E. coli. Plasmids were constructed to overexpress phosphomannose mutase (manB), α-(1,2)-fucosyltransferase (futC), and mannose-1-phosphate guanyltransferase (manC). Then, fermentation was carried out using glycerol, lactose and different concentrations of mannose culture media. The results showed that the Escherichia coli with knockout phosphomannose isomerase (manA) used mannose to synthesize GDP-fucose, thereby producing 2′-fucosyllactose with a higher conversion rate than the Escherichia coli with overexpression of phosphomannose isomerase (manA) on the plasmid. The Escherichia coli with further knockout of the UDP-glucose lipid carrier transferase (Wcaj) gene used mannose to synthesize GDP-fucose, thereby producing 2′-fucosyllactose with a further higher conversion rate than the Escherichia coli with knockout phosphomannose isomerase (manA).
[0086] The sequences of the above genes involved in knocking out and expressing during the strain construction process of the embodiment are shown in the sequence listing SEQ ID NO.1-15.
[0087] The present invention will be further described below by way of examples.
[0088] Example 1 Construction of chassis bacteria strain L
[0089] E. coli K12 MG1655ΔlacIZ::P trc -wcaG-gmd-lacy build
[0090] Using Escherichia coli MG1655 as the original strain, the P lac Promoter sequence and lacI, lacZ genes, and use P at the lacI, lacZ gene sites trc The promoter overexpresses wcaG, gmd, and lacy genes. trc The promoter is P trp Promoter and P lac The spliced promoter of the promoter has a lac Promoter with higher transcription efficiency.
[0091] The method used to construct this strain is λRed recombination. It mainly constructs a two-step homologous recombination fragment, using pKD46 (GenBank: MF287367) as a homologous recombination plasmid to knock out and integrate genes. The first step homologous recombination fragment contains upstream and downstream homologous arms, chloramphenicol resistance gene and sacB gene. The second step homologous recombination fragment contains upstream and downstream homologous arms and the gene to be integrated. The specific method is described in detail below:
[0092] 1. The first step is to construct the homologous recombination fragment mhpr-cat-sacB. Construct the cat-sacB gene fragment, where cat is the chloramphenicol resistance gene (SEQ ID NO.13) and sacB (SEQ ID NO.14) is derived from the pEX18Gm plasmid; use Escherichia coli MG1655 as a template, mhpr-up, mhpr-2, lacy-1 / lacy-down as primers, and PCR to obtain P lac The promoter fragment and the upstream and downstream homology arms of the lacIZ gene. Using the three fragments, including cat-sacB, and the upstream and downstream homology arms as templates, the first recombinant fragment mhpr-cat-sacB (lacI is not related to the expression of 2-FL) was obtained by overlapping PCR.
[0093] 2. Prepare E. coli MG1655 chemical transformation competent cells and transform the plasmid pKD46 into them.
[0094] 3. First step: homologous recombination. The constructed first recombination fragment mhpr-cat-sacB was electroporated into competent cells containing pKD46 plasmid, and the bacterial solution was applied to double-resistance LB plates containing ampicillin and chloramphenicol, cultured at 30°C for screening, inverted culture for 24 hours, and transformants were picked for colony PCR identification, with the starting strain MG1655 as a control.
[0095] 4. The second step homologous recombination fragment mhpr-P trc -wcaG-gmd-lacy was constructed. Using E. coli MG1655 as template, primers mhpr-up / mhpr-2, lacy-1-up / lacy-down were designed, and PCR was performed to obtain P lac The promoter fragment and the upstream and downstream homology arms of the lacIZ gene were obtained by PCR using the pTrc99a-wcaG-gmd plasmid as a template (the construction process of the pTrc99a-wcaG-gmd plasmid will be described in detail below) and mhpr-trc-up / wcaG-1-down as primers. trc The gene fragment to be integrated consisting of promoter, wcaG and gmd genes P trc -wcaG-gmd. The second recombinant fragment mhpr-P was obtained by overlapping PCR with three fragments. trc -wcaG-gmd-lacy. (The lacy gene in the second homologous recombination fragment comes from designing the lacy gene into the downstream homologous arm in the second recombination fragment)
[0096] 5. The second step is homologous recombination.
[0097] (1) The correct recombinants were identified in the first homologous recombination and prepared into electroporation competent cells.
[0098] (2) The second step homologous recombination fragment mhpr-P trc -wcaG-gmd-lacy was transferred into the competent cells of the first homologous recombination product, cultured in LB medium at 30°C for 3-4h, then transferred into LB liquid medium containing 10% sucrose, cultured at 37°C for 24h, streaked on LB solid plate containing 10% sucrose with an inoculation loop, cultured at 37°C for 12h, and single colonies were cultured on LB plate and LB plate containing chloramphenicol, respectively.
[0099] (3) Transformant verification: The corresponding colonies that cannot grow on the LB plate containing chloramphenicol were picked from the LB plate, and colony PCR verification was performed. Further sequencing verification was performed to obtain the target strain that underwent the second recombination, which was named strain L (see verification diagram Figure 2 ).
[0100] The construction method of the plasmid pTrc99a-wcaG-gmd required in the second step of homologous recombination is as follows: using pTrc99a plasmid (GenBank: U13872) as a template, using primers pTrc99a-GW-F / pTrc99a-BA-R, PCR amplification obtains a linear pTrc99a vector fragment containing the Ptrc promoter. Using Escherichia coli MG1655 as a template, using primers gmd-F / gmd-R and wcaG-F / wcaG-R, PCR amplification obtains wcaG and gmd gene fragments. Use seamless cloning enzyme pEASY-UniSeamlessCloning and Assembly Kit (all gold) to connect wcaG and gmd with the linear vector pTrc99a fragment. The ligation product was transformed into competent E. coli JM109 by heat shock, and transformants were screened on LB plates containing ampicillin. Plasmid extraction and sequencing were performed to obtain the successfully constructed plasmid pTrc99a-wcaG-gmd.
[0101] Table 1: Primers used to construct the recombinant strain L in Example 1
[0102]
[0103]
[0104] Example 2: Construction of strain L1 (knockout of manA gene)
[0105] Strain L1 was constructed using the strain L constructed in Example 1 as a chassis strain, and the manA (phosphomannose isomerase) gene on the genome was knocked out.
[0106] The strain was constructed using the λRed recombination technique. The main method is to construct a two-step homologous recombination fragment, using pKD46 (GenBank: MF287367) as a homologous recombination plasmid to knock out and integrate genes. The first step homologous recombination fragment contains the upstream and downstream homologous arms, the chloramphenicol resistance gene and the sacB gene. The second step homologous recombination fragment contains the upstream and downstream homologous arms.
[0107] The specific method is described in detail below:
[0108] 1. The first step is to construct the homologous recombination fragment up-cat-sacB-down. Construct the cat-sacB gene fragment, where cat is the chloramphenicol resistance gene and sacB comes from the pEX18Gm plasmid; use strain L as a template, and use manA-up-F / manA-up-R and manA-down-F / manA-down-R as primers to obtain the upstream and downstream homologous arms of the manA gene by PCR. Use cat-sacB(N)-F / cat-sacB-R as primers, and use the Escherichia coli that successfully recombined the first time in strain L as a template to obtain the cat-sacB fragment by PCR. Use three fragments, including cat-sacB and the upstream and downstream homologous arms of the manA gene as templates, and obtain the first recombinant fragment up-cat-sacB-down by overlapping PCR.
[0109] 2. Prepare chemical transformation competent cells of strain L and transform plasmid pKD46 into them.
[0110] 3. First step: homologous recombination. The constructed first recombination fragment up-cat-sacB-down was electroporated into the competent cells of strain L containing the pKD46 plasmid. The bacterial solution was spread on a double-resistance LB plate containing ampicillin and chloramphenicol, cultured at 30°C for screening, inverted cultured for 24 hours, and transformants were picked for colony PCR identification, with the starting strain L as the control.
[0111] 4. Construction of the second homologous recombination fragment up-down. Using E. coli MG1655 as a template, manA-up-F / manA-up-qcs-R and manA-down-qcs-F / manA-down-R as primers, PCR was used to obtain the upstream and downstream homologous arms of the manA gene, and the second recombination fragment up-down was obtained by overlapping PCR using the above homologous arms as templates.
[0112] 5. The second step is homologous recombination.
[0113] (1) The correct recombinants were identified in the first homologous recombination and prepared into electroporation competent cells.
[0114] (2) The second homologous recombination fragment was transferred up-down into the first homologous recombination competent cells, cultured in LB medium at 30°C for 3-4 h, and then transferred to LB liquid medium containing 10% sucrose. Cultured at 37°C for 24 h, streaked with an inoculation loop on a LB solid plate containing 10% sucrose, and cultured at 37°C for 12 h. Single colonies were cultured on LB plates and LB plates containing chloramphenicol.
[0115] (3) Transformant verification: The corresponding colonies that could not grow on the LB plate containing chloramphenicol were picked from the LB plate, and colony PCR verification was performed. Further sequencing verification was performed to obtain the target strain that underwent the second recombination, which was named strain L1 (see the verification figure). Figure 3 ).
[0116] Table 2: Primers used to construct genome knockout of manA gene
[0117] Primer Name Sequence manA-up-F gtttcctgatagagatacgtcttg manA-up-R aatgtggaaattaatcccactattaaagca cat-sacB(N)-F Gggattaatttccacattatgtcgagtaagttagtactggtt cat-sacB-R aattttttcagtaagctctggtgttaccggtgttcaga manA-down-F gagcttactgaaaaaattaacatctctt manA-down-R cgtcattgaccagatccga manA-down-qcs-F gagcttactgaaaaaattaacatctcttg manA-up-qcs-R caagagatgttaattttttcagtaagctcaatgtggaaattaatcccactattaaagca
[0118] Example 3: Construction of strain L2 (knockout of wcaj gene)
[0119] Construct strain L2, use strain L1 as the chassis strain, knock out the UDP-glucose lipid carrier transferase encoding gene (Wcaj) on the genome, and construct this strain using cas9. Mainly, the first step of homologous recombination fragments are constructed to include upstream and downstream homologous arms, chloramphenicol resistance genes and N20 genes (SEQ ID NO.15), and then electrophoretically transferred into the chassis strain that needs to be knocked out. After Escherichia coli grows in screening medium with different resistances, the Escherichia coli that successfully recombined in the first step is induced to express Pcago plasmids to produce cas9 proteins to screen the fragments that are successfully recombined. The specific method is described in detail below:
[0120] 1. The first step is to construct the homologous recombination fragment up-cat-N20-down. Construct the cat-N20 gene fragment, where cat is the chloramphenicol resistance gene and N20 is derived from the Pcago plasmid. Use primers Wcm-1 / Wcm20-2 for overlapping PCR to obtain the cat-N20 fragment. Use strain L as a template, up-1 / up-2 and down-1 / down-2 as primers, and PCR to obtain the upstream and downstream homologous arms of the Wcaj gene. Using three fragments, including cat-N20, and the upstream and downstream homologous arms of Wcaj as templates, the first recombination fragment up-cat-N20-down was obtained by overlapping PCR.
[0121] 2. Prepare Escherichia coli L1 chemical transformation competent cells and transform the plasmid pCAGO into them (pCAGO plasmid is a prior art, and its preparation method is detailed in: Zhao, D., et al. CRISPR / Cas9-assisted gRNA-free one-step genome editing with no sequence limitations and improved targeting efficiency. Scientific Reports. DOI: 10.1038 / s41598-017-16998-8).
[0122] 3. First step: homologous recombination. The constructed first recombination fragment up-cat-N20-down was electroporated into L1 competent cells containing pCAGO plasmid, and the bacterial solution was applied to double-resistance LB plates containing ampicillin and chloramphenicol (1% glucose), cultured at 30°C for screening, inverted culture for 24 hours, and transformants were picked for colony PCR identification, with the starting strain Escherichia coli L1 as a control.
[0123] 4. The second step is reorganization.
[0124] The first recombinant bacteria were verified by colony PCR, and the correct bacteria were transferred to a 5ml LB test tube containing 5 μl AMP resistance, 5 μl IPTG (final concentration 0.1M) and 100 μl arabinose (final concentration 2g / L, with mother solution 1g / 10ml), and the expression of CRISPR / Cas9 system and λ-red protein was induced. The cells were cultured at 30°C for more than 6 hours, and single colonies were isolated. The isolated single colonies were plated, and single colonies that did not grow on chloramphenicol medium and grew on ampicillin medium were screened for colony PCR identification. The starting strain Escherichia coli L1 was used as a control. After that, the identified Escherichia coli was subcultured in LB medium at 37°C (passed for 4 generations), and the Pcago plasmid was discarded, and the strain was named L2 (see the verification figure). Figure 4 ).
[0125] Table 3: Primers used to construct genome knockout of Wcaj gene
[0126] Primer Name Sequence up-1: TCACCACTTTGTCGTTCTCCATCACTTTC up-2 AACGATGACAAATCTAAAAAAGCGCG wcm-1 TTTTTAGATTTGTCATCGTTATTAATTAATCTCGAGTGTGACG wcm20-2 GCGCCATAAGGTGAAACCGGCCTTACTTCGGTTCGATGGACTATTACGCCCCGCCCTGCCAC down-1 CCGGTTTCACCTTATGGCGCAGCATGTAGCCTTCAATGAGGTTCCTGTTATTAGCCCCTTACCC down-2 AACGCGGTCGCTATCAGCAAATCAACCTG
[0127] Example 4: Construction of plasmid pSB4K5-futC-manC
[0128] To overexpress futC and manC genes at low copy numbers, plasmid pSB4K5-futC-manC needs to be constructed, in which biobrick108 promoter is used to overexpress futC and manC genes.
[0129] Construction of pSB4K5-futC-manC plasmid: Using pSB4K5 plasmid as template, primers psb4k5-2 / j23100-R, PCR amplification was performed to obtain a linear pSB4K5 vector fragment. The α-(1,2)-fucosyltransferase gene futC (shown in SEQ ID NO.10) from Helicobacter pylori was selected, and primers j23108-F / PSB-FUTC-C(G)-R were used to a pUC57 plasmid carrying the fully synthesized futC as a template, and PCR amplification was performed to obtain a futC gene fragment, wherein the futC gene was partially codon optimized. Using primers PSB4K5-FUtc-manC-F / psb4k5-futc-R and strain L as template, PCR amplification was performed to obtain the manC gene fragment, and seamless cloning enzyme was used to connect futC with the linear vector pSB4K5 fragment and the manC gene fragment. The ligation product was transformed into competent Escherichia coli JM109 by heat shock, and the transformants were screened on LB plates containing kanamycin. Plasmid extraction and sequencing verification were performed to obtain the successfully constructed plasmid pSB4K5-futC-manC.
[0130] Table 4: Primers used to construct plasmid pTrc99a-futC-manC
[0131]
[0132]
[0133] Example 5: Construction of plasmid pTrc99a-manB-manA
[0134] The plasmid construction process is as follows: using the pTrc99a plasmid as a template, using primers pTrc99a-1 / pTrc99a-2, PCR amplification to obtain a linear pTrc99a vector. Using wild-type E. coli MG1655 genomic DNA as a template, PCR amplification was performed using primers manB-F / manB-R and manA-F / manA-R to obtain manB gene and manA gene, and seamless cloning enzyme was used to connect manB and manA to the pTrc99a linear vector fragment. The connection product was transformed into the competent state of E. coli JM109 by heat shock, and the transformants were screened on LB plates containing ampicillin, and sequencing verification was performed to obtain the successfully constructed plasmid pTrc99a-manB-manA.
[0135] Table 5: Primers used to construct plasmid pTrc99a-manB-manA
[0136] Primer Sequence manB-F tttgtttaactttaagaaggagatatacatatgaaaaaattaacctgctttaaagc manB-R tctccttcttaaagttaaacaaattactcgttcagcaacgtca manA-F gtttaactttaagaaggagatatacatatgcaaaaactcattaactcagtg manA-R tctagaggatccccgggtacttacagcttgttgtaaacacgc pTrc99a-2 gtgtttacaacaagctgtaagtacccggggatcctctaga pTrc99a-1 tctccttcttaaagttaaacaaacacaattccacacattatacgagc
[0137] Example 6: Construction of plasmid pTrc99a-manB
[0138] The plasmid construction process is as follows: pTrc99a plasmid was used as a template, and primers 99a-sim-f / vector-3 were used to PCR amplify the linear pTrc99a vector. Wild-type E. coli MG1655 genomic DNA was used as a template, and TmanB-F / 99a-sim-r were used as primers to perform PCR amplification to obtain the manB gene. Seamless cloning enzyme was used to connect manB and pTrc99a linear vector fragments. The connection product was transformed into competent E. coli JM109 by heat shock, and transformants were selected on LB plates containing ampicillin. Plasmid extraction and sequencing verification were performed to obtain the successfully constructed plasmid pTrc99a-manB.
[0139] Table 6: Primers used to construct plasmid pTrc99a-manB
[0140] Primers sequence 99a-sim-f agatataccgaattcgagctcg Vector-3 aagttaaacaaaggtctgtttcctgtgtgagattgttatccgctc TmanB-F aacagacctttgtttaactttaagaaggagatataccatgaaaaaattaacctgctt 99a-sim-r agctcgaattcggtatatctttactcgttcagcaacgtca
[0141] Example 7: Construction of 2′-fucosyllactose producing strain
[0142] To achieve the production of 2′-fucosyllactose, the following genetically engineered strains need to be constructed:
[0143] Strain L3: Use strain L1 as the base to transform the pSB4K5-futC-manC and pTrc99a-manb-mana plasmids;
[0144] Strain L4: Use strain L1 as the base strain to transform into plasmids pSB4K5-futC-manC and pTrc99a-manb;
[0145] Strain L5 (to further verify the effect of knocking out Wcaj on the synthesis of GDP-fucose and then 2′-fucosyllactose by E. coli using mannose): the constructed strain L2 was used as the chassis strain to transform into the pSB4K5-futC-manC and pTrc99a-manb-mana plasmids;
[0146] Strain L6: Use strain L2 as the chassis to transform the plasmids pSB4K5-futC-manC and pTrc99a-manb.
[0147] The verification diagrams of the successfully constructed strains L3, L4, L5, and L6 are shown in Figure 5-10 .
[0148] Example 8: Fermentation verification of 2′-fucosyllactose producing strain
[0149] The strains L3, L4, L5, and L6 constructed in Example 7 were respectively used as experimental strains, and fermented and cultured, and HPLC was used to detect and analyze 2′-fucosyllactose. The fermentation and detection process is as follows:
[0150] LB medium (1 L): Tryptone 10 g, Yeast Extract 5 g, NaCl (sodium chloride) 5 g, and the rest is water.
[0151] Fermentation medium: 2g / L KH2PO4, 2g / L NH4C1, 1.7g / L citric acid, 1.4g / L MgSO4.7H2O, 5g / L yeast powder, 10mL / L trace element solution, different concentrations of mannose (0g / L, 1g / L, 5g / L, 10g / L respectively), 10g / L glycerol, 5g / L lactose, and the rest is water; adjust the pH to about 7.0;
[0152] Trace element solution: 10g / L FeSO4·7H2O, 2.2g / L ZnSO·7H2O, 1.0g / L CuSO4·5H2O, 0.38g / L MnSO4·H2O, 0.02g / L Na2B4O7·10H2O, 0.1g / L (NH4)6Mo7O 24 , 2.0g / L CaCl2, the rest is water;
[0153] The method for producing 2′-fucosyllactose by fermentation of recombinant Escherichia coli L3, L4, L5, and L6 is as follows:
[0154] (1) Pick out the obtained single colonies of genetically engineered strains L3, L4, L5, and L6 and transfer them into 5 mL of LB liquid medium, add ampicillin and kanamycin (final concentration 50 μg / mL), and culture at 37°C and 220 r / min overnight;
[0155] (2) The bacterial liquid was transferred to 1 mL of fermentation medium (24-well plate) with an inoculum size of 2%. Ampicillin and kanamycin (final concentration 50 μg / mL) were added. After culturing at 37°C and 600 rpm for 48 h, 1 mL of the sample was taken to detect the production of 2′-fucosyllactose and the utilization of mannose in the culture medium.
[0156] (3) After collecting the E. coli fermentation broth, the fermentation broth was disrupted by ultrasonic cell disruption, boiled for ten minutes, centrifuged for 10 minutes, and samples were prepared for HPLC analysis to detect the production of 2′-fucosyllactose and the remaining amount of mannose in the fermentation broth. The results were averaged from three parallel runs.
[0157] Table 6 2′-fucosyllactose yield (g / L)
[0158]
[0159]
[0160] Table 7 Remaining amount of mannose in the culture medium after fermentation (g / L)
[0161]
[0162] Table 8 Conversion rate of mannose to 2′-fucosyllactose in culture medium
[0163] Initial mannose concentration L3 L4 L5 L6 1g / L 63.55%±2% 89.1%±1.6% 88%±0.8% 96.2%±1.5% 5g / L 20.20%±0.2% 42.61%±3.29% 21.34%±0.62% 58.69%±1.48% 10g / L 10.77%±0.1% 51.63%±1.67% 12.68%±0.34% 53.80%±1.13%
[0164] Note: Conversion rate of mannose to 2′-fucosyllactose in L3, L5, L4, L6 = (actual yield of 2′-fucosyllactose - yield of 2′-fucosyllactose after fermentation when mannose in the culture medium is 0 g) / [(relative molecular weight of 2′-fucosyllactose / relative molecular weight of mannose) × utilization of mannose g];
[0165] The purpose of constructing strains L3 and L5 is to compare L4 and L6 to explore the influence of the manA gene on mannose utilization. The results in Table 8 show that the conversion rate of mannose to 2′-fucosyllactose in L4 and L6 without manA gene is improved. As shown in Table 7, mannose in the culture medium of L3 and L5 containing manA gene is basically consumed, while there is still a large amount of mannose remaining in the culture medium of L4 and L6. Combined with the 2′-fucosyllactose data in Table 6, it can be explained that most of the mannose in the culture medium of Escherichia coli with manA gene is used for the growth metabolism of Escherichia coli, but not for the synthesis of GDP-fucose and then the synthesis of 2′-fucosyllactose. A large amount of mannose remains in the culture medium of Escherichia coli with manA knocked out, indicating that mannose is not used by Escherichia coli for its own growth metabolism, that is, the purpose of separating the growth of Escherichia coli from the production of 2′-fucosyllactose by mannose fermentation is achieved.
[0166] The core idea of the present invention is to provide a method for transforming Escherichia coli so that its growth and production metabolism are separated, using conventional carbon sources such as glycerol for growth, and using mannose as a carbon source to produce 2′-fucosyllactose. The ability of the strain to produce 2′-fucosyllactose by mannose fermentation was verified by adding different concentrations of mannose to the culture medium. The results showed that the transformed strain increased the conversion rate of mannose to 2′-fucosyllactose, and the yield of 2′-fucosyllactose increased with the increase of mannose content.
[0167] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention. SEQUENCE LISTING <110> Tianjin University of Science and Technology Shandong Synthetic Vision Biotechnology Co., Ltd. <120> Recombinant Escherichia coli for synthesizing 2'-fucosyllactose using mannose and its application <130> 1 <160> 15 <170> PatentIn version 3.5 <210> 1 <211> 94 <212> DNA <213> Escherichia coli MG1655 <400> 1 taacgttatact ggtttcacat tcaccaccct gaattgactc tcttccgggc gctatcatgc 60 cataccgcga aaggttttgc gccattcgat ggtg 94 <210> 2 <211> 1082 <212> DNA <213> Escherichia coli MG1655 <400> 2 gtgaaaccag taacgttata cgatgtcgca gagtatgccg gtgtctctta tcagaccgtt 60 cccgcgtggt gaaccaggcc agccacgttt ctgcgaaaac gcgggaaaaa gtggaagcgg 120 cgatggcgga gctgaattac attcccaacc gcgtggcaca acaactggcg ggcaaacagt 180 cgttgctgat tggcgttgcc acctccagtc tggccctgca cgcgccgtcg caaattgtcg 240 cggcgattaa atctcgcgcc gatcaactgg gtgccagcgt ggtggtgtcg atggtagaac 300 gaagcggcgt cgaagcctgt aaagcggcgg tgcacaatct tctcgcgcaa cgcgtcagtg 360 ggctgatcat taactatccg ctggatgacc aggatgccat tgctgtggaa gctgcctgca 420 ctaatgttcc ggcgttattt cttgatgtct ctgaccagac acccatcaac agtattattt 480 tctcccatga agacggtacg cgactgggcg tggagcatct ggtcgcattg ggtcaccagc 540 aaatcgcgct gttagcgggc ccattaagtt ctgtctcggc gcgtctgcgt ctggctggct 600 ggcataaata tctcactcgc aatcaaattc agccgatagc ggaacgggaa ggcgactgga 660 gtgccatgtc cggttttcaa caaaccatgc aaatgctgaa tgagggcatc gttcccactg 720 cgatgctggt tgccaacgat cagatggcgc tgggcgcaat gcgcgccatt accgagtccg 780 ggctgcgcgt tggtgcggat atctcggtag tgggatacga cgataccgaa gacagctcat 840 gttatatccc gccgttaacc accatcaaac aggattttcg cctgctgggg caaaccagcg 900 tggaccgctt gctgcaactc tctcagggcc aggcggtgaa gggcaatcag ctgttgcccg 960 tctcactggt gaaaagaaaa accaccctgg cgcccaatac gcaaaccgcc tctccccgcg 1020 cgttggccga ttcattaatg cagctggcac gacaggtttc ccgactggaa agcgggcagt 1080 ga 1082 <210> 3 <211> 3075 <212> DNA <213> Escherichia coli MG1655 <400> 3 atgaccatga ttacggattc actggccgtc gttttacaac gtcgtgactg ggaaaaccct 60 ggcgttaccc aacttaatcg ccttgcagca catccccctt tcgccagctg gcgtaatagc 120 gaagaggccc gcaccgatcg cccttcccaa cagttgcgca gcctgaatgg cgaatggcgc 180 tttgcctggt ttccggcacc agaagcggtg ccggaaagct ggctggagtg cgatcttcct 240 gaggccgata ctgtcgtcgt cccctcaaac tggcagatgc acggttacga tgcgcccatc 300 tacaccaacg tgacctatcc cattacggtc aatccgccgt ttgttcccac ggagaatccg 360 acgggttgtt actcgctcac atttaatgtt gatgaaagct ggctacagga aggccagacg 420 cgaattattt ttgatggcgt taactcggcg tttcatctgt ggtgcaacgg gcgctgggtc 480 ggttacggcc aggacagtcg tttgccgtct gaatttgacc tgagcgcatt tttacgcgcc 540 ggagaaaacc gcctcgcggt gatggtgctg cgctggagatg acggcagtta tctggaagat 600 caggatatgt ggcggatgag cggcattttc cgtgacgtct cgttgctgca taaaccgact 660 acacaaatca gcgatttcca tgttgccact cgctttaatg atgatttcag ccgcgctgta 720 ctggaggctg aagttcagat gtgcggcgag ttgcgtgact acctacgggt aacagtttct 780 ttatggcagg gtgaaacgca ggtcgccagc ggcaccgcgc ctttcggcgg tgaaattatc 840 gatgagcgtg gtggttatgc cgatcgcgtc acactacgtc tgaacgtcga aaacccgaaa 900 ctgtggagcg ccgaaatccc gaatctctat cgtgcggtgg ttgaactgca caccgccgac 960 ggcacgctga ttgaagcaga agcctgcgat gtcggtttcc gcgaggtgcg gattgaaaat 1020 ggtctgctgc tgctgaacgg caagccgttg ctgattcgag gcgttaaccg tcacgagcat 1080 catcctctgc atggtcaggt catggatgag cagacgatgg tgcaggatat cctgctgatg 1140 aagcagaaca actttaacgc cgtgcgctgt tcgcattatc cgaaccatcc gctgtggtac 1200 acgctgtgcg accgctacgg cctgtatgtg gtggatgaag ccaatattga aacccacggc 1260 atggtgccaa tgaatcgtct gaccgatgat ccgcgctggc taccggcgat gagcgaacgc 1320 gtaacgcgaa tggtgcagcg cgatcgtaat cacccgagtg tgatcatctg gtcgctgggg 1380 aatgaatcag gccacggcgc taatcacgac gcgctgtatc gctggatcaa atctgtcgat 1440 ccttcccgcc cggtgcagta tgaaggcggc ggagccgaca ccacggccac cgatattatt 1500 tgcccgatgt acgcgcgcgt ggatgaagac cagcccttcc cggctgtgcc gaaatggtcc 1560 atcaaaaaat ggctttcgct acctggagag acgcgcccgc tgatcctttg cgaatacgcc 1620 cacgcgatgg gtaacagtct tggcggtttc gctaaatact ggcaggcgtt tcgtcagtat 1680 ccccgtttac agggcggctt cgtctgggac tgggtggatc agtcgctgat taaatatgat 1740 gaaaacggca acccgtggtc ggcttacggc ggtgattttg gcgatacgcc gaacgatcgc 1800 cagttctgta tgaacggtct ggtctttgcc gaccgcacgc cgcatccagc gctgacggaa 1860 gcaaaacacc agcagcagtt tttccagttc cgtttatccg ggcaaaccat cgaagtgacc 1920 agcgaatacc tgttccgtca tagcgataac gagctcctgc actggatggt ggcgctggat 1980 ggtaagccgc tggcaagcgg tgaagtgcct ctggatgtcg ctccacaagg taaacagttg 2040 attgaactgc ctgaactacc gcagccggag agcgccgggc aactctggct cacagtacgc 2100 gtagtgcaac cgaacgcgac cgcatggtca gaagccgggc acatcagcgc ctggcagcag 2160 tggcgtctgg cggaaaacct cagtgtgacg ctccccgccg cgtcccacgc catcccgcat 2220 ctgaccacca gcgaaatgga tttttgcatc gagctgggta ataagcgttg gcaatttaac 2280 cgccagtcag gctttctttc acagatgtgg attggcgata aaaaacaact gctgacgccg 2340 ctgcgcgatc agttcacccg tgcaccgctg gataacgaca ttggcgtaag tgaagcgacc 2400 cgcattgacc ctaacgcctg ggtcgaacgc tggaaggcgg cgggccatta ccaggccgaa 2460 gcagcgttgt tgcagtgcac ggcagataca cttgctgatg cggtgctgat tacgaccgct 2520 cacgcgtggc agcatcaggg gaaaacctta tttatcagcc ggaaaaccta ccggattgat 2580 ggtagtggtc aaatggcgat taccgttgat gttgaagtgg cgagcgatac accgcatccg 2640 gcgcggattg gcctgaactg ccagctggcg caggtagcag agcgggtaaa ctggctcgga 2700 ttagggccgc aagaaaacta tcccgaccgc cttactgccg cctgttttga ccgctgggat 2760 ctgccattgt cagacatgta taccccgtac gtcttcccga gcgaaaacgg tctgcgctgc 2820 gggacgcgcg aattgaatta tggcccacac cagtggcgcg gcgacttcca gttcaacatc 2880 agccgctaca gtcaacagca actgatggaa accagccatc gccatctgct gcacgcggaa 2940 gaaggcacat ggctgaatat cgacggtttc catatgggga ttggtggcga cgactcctgg 3000 agcccgtcag tatcggcgga attccagctg agcgccggtc gctaccatta ccagttggtc 3060 tggtgtcaaa aataa 3075 <210> 4 <211> 279 <212> DNA <213> Artificial Sequence <400> 4 gcgaattgat ctggtttgac agcttatcat cgactgcacg gtgcaccaat gcttctggcg 60 tcaggcagcc atcggaagct gtggtatggc tgtgcaggtc gtaaatcact gcataattcg 120 tgtcgctcaa ggcgcactcc cgttctggat aatgtttttt gcgccgacat cataacggtt 180 ctggcaaata ttctgaaatg agctgttgac aattaatcat ccggctcgta taatgtgtgg 240 aattgtgagc ggataacaat ctcacacagg aaacagacc 279 <210> 5 <211> 966 <212> DNA <213> Escherichia coli MG1655 <400> 5 ttacccccga aagcggtctt gattctcaag gaaccactgg taagtgctgg caagccccgc 60 ttccagtgag atttcgtgat accagccaag ctgatgcagg cgcgtcacat ccagcagttt 120 gcgcggcgtg ccatccggtt tgctggcatc aaaaaccacc cggcctttgt aacccaccac 180 tttggcgatg gtttgcgcca gctcgcggat agtgcagtca acgcccgtgc cgacgttaat 240 gtgcgacaac atcggctggg tgttctccag ccagacttca tgcgccagct ccatgacatg 300 aatgctcgcc gccgccatat catcgacgtg cagaaattcg cgcatcggtg taccgctgcc 360 ccataccacc acgtccggcg cattctgtgc cgtcgcctcg tggaagcgac gcagcaatgc 420 tgggatcaca tgcgaattac tcgggtggaa gttgtcgtgt ggcccgtaca ggttggtcgg 480 catgactgag cggtaatcgc gtccgtactg gcggttgtat gattcgcaca gtttgatccc 540 ggcgattttg gcaatagcat aaggctcgtt agtcggctcc agcgtgccct gcaacaactc 600 gctttctgcc atcggctgtt ttgccagttt cgggtagatg caggacgatc cgagaaacag 660 cagtttgttc acgtcgttct gatgcgcggc gtgaatgatg ttgctctcaa tcatcatgtt 720 ctggtagatg aaatccgccg gataggtgtt gttggcaaca atgccgccca ctttcgccgc 780 cgccagatag acctggtcaa tacgttcgct ggcaaagaaa tcatgcacgg cgcggctgtc 840 cagcaggttc agctcgtcgc gggtgcgtaa taccagttcc acatcaccgc gctgttcgag 900 ctgccgcctg atggcggaac cgaccatccc gcgatgacca gcaataaaaa ctcgttgttt 960 actcat 966 <210> 6 <211> 1122 <212> DNA <213> Escherichia coli MG1655 <400> 6 ttatgactcc agcgcgatcg ccacgtcgta gccgtgagat ttcagcagag agtgtttttt 60 cgccgcttcg aggtcattag ccaccatttc agacaccatc tctctgaggg tgatttccgg 120 tttccagccc agtttttcgt gcgctttggt cgggtcgccg agcagcgttt caacttcagc 180 cggacggaag taacgcgggt caacagcgat aatcacatca cccggtttaa cgcccggcgc 240 gtcatgcccg gtgacggaaa ccacaatgcc cttctcttca acgcccgtgc cttcaaagcg 300 cagtttgatg cccagctgtg ctgccgccat ttccacgaac tgacgcacgg agtactgaac 360 gccggtcgcg ataacgaaat cttccggctg ttcctgctgc agcatcatcc actgcatttt 420 tacgtagtct ttggcgtggc cccagtcacg cagggaatcc atattgccga ggtacaggca 480 cgactccagc ccctgggcga tgttggcgat tgcgcgggtg attttgcggg taacgaaggt 540 ttcgccgcgg cgcggggatt catggttgaa gagaattccg ttacaggcgt acatgccgta 600 ggattcacgg tagttaacgg tgatccagta ggcgtacagt ttggcgaccg catacggaga 660 tcgcgggtag aacggcgtgg tctctttctg cggaatttcc tgcaccagac catacagttc 720 agaggtggaa gcctgataga aacgagtttt cttttccaga ccgaggaagc ggatcgcctc 780 cagcaggcgc agcgtaccca tcgcgtcgac gtcagcggta tattctggtg actcaaaaga 840 gaccgcaacg tggctcattg cgcccaggtt gtacacttca tccggctgta cttcacgcaa 900 aatgcgcgtc aggttagagg tatcactcag gtcgccataa tgcagatgga atttcgggtt 960 gcaggtgtgc ggatcctgat aaatgtgatc cacgcgctcg gtgttgaatg acgatgcgcg 1020 acgcttaata ccatgcacct cgtaaccttt ttccagcaga aactctgcca ggtaagaacc 1080 gtcttgtccg gttacaccgg tgatgagagc gacttttgac at 1122 <210> 7 <211> 1254 <212> DNA <213> Escherichia coli MG1655 <400> 7 ttaagcgact tcattcacct gacgacgcag cagggaaagc gggccggggc cgctaagcgt 60 gaacacggaa attaaggtga agcccagcgc caccagaccc agcaccagat aagcgccctg 120 gaaaccgatg ctttcataca tattgcccgc cagtacagac ataaaaatca tcgccagttg 180 cttaaagaag cagaaacaga ccagataaat cgtcgctgaa aaacgcactt caaactggct 240 ggtaatatat ttaaagcagc ccaccagcag gaacggtact tcaaacatat gcagcgtttt 300 cagaataacc acttccagcg ctgaggtggc gaacgatgag ccaataatac gtacagacat 360 aatagtgcca gccagcagca gggcgttttt cccaccgatg cgattaatga tcagtggcgc 420 aaagaacata atcgaggcgt taagtaattc gcccattgtc gttacgtagc caatacccg 480 cgtaccctgt tcaccggtag siagaacga agtaagaaa ttagcaact gttggtcaaa 540 aacatcgtag gtgcaggaaa cgccaatac atacagtgac aaaaaccaca gttttggctg 600 tctgaacagt tccagtgcca gcttaggct aaatgccgaa tggttggcac ctaccgcatt 660 ggcaacgtg gcagaagagg gcgcatccgt ttggcgaa aagagtaaaa cggcgaggat 720 gagtgcacag ccagagccca gccagaaaac aactgatta ttgatggtga acatgatgcc 780 gatacgag gcacacagcg cccagccaac acagccaac atccgcgcgc gaccaattc 840 gaaattactg cgacggctga ctttctcaat aaatgcctct actgctggcg caccggcgtt 900 aaaacaaag cctagataaa taccaccaac atcgatccct actaaaatgt tgtattgtaa 960 cagtggcccg aagataaaaaaagaacgg cgcaaacatc actaacatgc cggtaataat 1020 ccacagcagg tatttgcgca gcccgagtttt gtcagaaagc agaccaaca gcggttggaa 1080 taatagcgag aacagagaaa tagcggcaa ataataccc gtacacttt tgctgatatg 1140 gttgatgtca tgtagccaaa tcgggaaaaa cgggaagtag gctcccatga taaaaaagta 1200 aaagaaaaag aataaaccga acatccaaaa gtttgtgttt tttaaatagt acat 1254 <210> 8 <211> 1176 <212> DNA <213> Escherichia coli MG1655 <400> 8 atgcaaaaac tcattaactc agtgcaaaac tatgcctggg gcagcaaaac ggcgttgact 60 gaactttatg gtatggaaaa tccgtccagc cagccgatgg ccgagctgtg gatgggcgca 120 catccgaaaa gcagttcacg agtgcagaat gccgccggag atatcgtttc actgcgtgat 180 gtgattgaga gtgataaatc gactctgctc ggagaggccg ttgccaaacg ctttggcgaa 240 ctgcctttcc tgttcaaagt attatgcgca gcacagccac tctccattca ggttcatcca 300 aacaaacaca attctgaaat cggttttgcc aaagaaaatg ccgcaggtat cccgatggat 360 gccgccgagc gtaactataa agatcctaac cacaagccgg agctggtttt tgcgctgacg 420 cctttccttg cgatgaacgc gtttcgtgaa ttttccgaga ttgtctccct actccagccg 480 gtcgcaggtg cacatccggc gattgctcac tttttacaac agcctgatgc cgaacgttta 540 agcgaactgt tcgccagcct gttgaatatg cagggtgaag aaaaatcccg cgcgctggcg 600 attttaaaat cggccctcga tagccagcag ggtgaaccgt ggcaaacgat tcgtttaatt 660 tctgaatttt acccggaaga cagcggtctg ttctccccgc tattgctgaa tgtggtgaaa 720 ttgaaccctg gcgaagcgat gttcctgttc gctgaaacac cgcacgctta cctgcaaggc 780 gtggcgctgg aagtgatggc aaactccgat aacgtgctgc gtgcgggtct gacgcctaaa 840 tacattgata ttccggaact ggttgccaat gtgaaattcg aagccaaacc ggctaaccag 900 ttgttgaccc agccggtgaa acaaggtgca gaactggact tcccgattcc agtggatgat 960 tttgccttct cgctgcatga ccttagtgat aaagaaacca ccattagcca gcagagtgcc 1020 gccattttgt tctgcgtcga aggcgatgca acgttgtgga aaggttctca gcagttacag 1080 cttaaaccgg gtgaatcagc gtttattgcc gccaacgaat caccggtgac tgtcaaaggc 1140 cacggccgtt tagcgcgtgt ttacaacaag ctgtaa 1176 <210> 9 <211> 1371 <212> DNA <213> Escherichia coli MG1655 <400> 9 atgaaaaaat taacctgctt taaagcctat gatattcgcg ggaaattagg cgaagaactg 60 aatgaagata tcgcctggcg cattggtcgc gcctatggcg aatttctcaa accgaaaacc 120 attgtgttag gcggtgatgt ccgcctcacc agcgaaacct taaaactggc gctggcgaaa 180 ggtttacagg atgcgggcgt tgacgtgctg gatattggta tgtccggcac cgaagagatc 240 tatttcgcca cgttccatct cggcgtggat ggcggcattg aagttaccgc cagccataat 300 ccgatggatt ataacggcat gaagctggtt cgcgaggggg ctcgcccgat cagcggagat 360 accggactgc gcgacgtcca gcgtctggct gaagccaacg actttcctcc cgtcgatgaa 420 accaaacgcg gtcgctatca gcaaatcaac ctgcgtgacg cttacgttga tcacctgttc 480 ggttatatca atgtcaaaaa cctcacgccg ctcaagctgg tgatcaactc cgggaacggc 540 gcagcgggtc cggtggtgga cgccattgaa gcccgcttta aagccctcgg cgcgcccgtg 600 gaattaatca aagtgcacaa cacgccggac ggcaatttcc ccaacggtat tcctaaccca 660 ctactgccgg aatgccgcga cgacacccgc aatgcggtca tcaaacacgg cgcggatatg 720 ggcattgctt ttgatggcga ttttgaccgc tgtttcctgt ttgacgaaaa agggcagttt 780 attgagggct actacattgt cggcctgttg gcagaagcat tcctcgaaaa aaatcccggc 840 gcgaagatca tccacgatcc acgtctctcc tggaacaccg ttgatgtggt gactgccgca 900 ggtggcacgc cggtaatgtc gaaaaccgga cacgccttta ttaaagaacg tatgcgcaag 960 gaagacgcca tctatggtgg cgaaatgagc gcccaccatt acttccgtga tttcgcttac 1020 tgcgacagcg gcatgatccc gtggctgctg gtcgccgaac tggtgtgcct gaaagataaa 1080 acgctgggcg aactggtacg cgaccggatg gcggcgtttc cggcaagcgg tgagatcaac 1140 agcaaactgg cgcaacccgt tgaggcgatt aaccgcgtgg aacagcattt tagccgtgag 1200 gcgctggcgg tggatcgcac cgatggcatc agcatgacct ttgccgactg gcgctttaac 1260 ctgcgcacct ccaataccga accggtggtg cgcctgaatg tggaatcgcg cggtgatgtg 1320 ccgctgatgg aagcgcgaac gcgaactctg ctgacgttgc tgaacgagta a 1371 <210> 10 <211> 906 <212> DNA <213> Helicobacter pylori <400> 10 atggctttta aagtggtgca aatttgcgga gggcttggga atcaaatgtt tcaatacgct 60 ttcgctaaaa gtttgcaaaa acactctaat acgcctgtgc tgttagatat tactttttt 120 gattggagca ataggaaaat gcaattagag cttttcccta ttgatttacc ctatgcgaat 180 gcaaaagaaa tcgctatagg taaaatgcaa cacctcccca agctagtaag agatacgctc 240 aaatacatgg gatttgatag ggtgagtcaa gaaatcgtgt ttgaatacga gcctaaattg 300 ttaaagccaa gccgcttgac ttatttttat ggctattttc aagatccacg atattttgat 360 gctatatccc ctttaatcaa gcaaactttc accctacccc acccccccccc ccccgaaaat 420 ggaaataata aaaaaaaaga ggaagaatac caccgcaaac ttgctttgat tttagccgct 480 caaaacagcg tgtttgtgca tataagaaga ggggattatg tggggattgg ctgtcagctt 540 ggcattgact atcaaaaaaa ggcgcttgag tatatggcaa aacgcgtgcc aaacatggaa 600 cttttcgtgt tttgcgaaga cttagaattc acgcaaaatc ttgatcttgg ctaccctttt 660 atggacatga ccactaggga tagagaagaa gaggcgtatt gggatatgct gctcatgcaa 720 tcctgtcagc atggcattat cgctaatagc acttatagct ggtgggcggc ttatttgata 780 gaaaatccag aaaaaatcat tattggcccc aaacactggc tttttgggca tgagaatatc 840 ctttgtgagg aatgggtgaa aatagaatcc cattttgagg taaaatccca aaagtataac 900 gcttaa 906 <210> 11 <211> 1437 <212> DNA <213> Escherichia coli MG1655 <400> 11 atggcgcagt cgaaactcta tccagttgtg atggcaggtg gctccggtag ccgcttatgg 60 ccgctttccc gcgtacttta tcccaagcag tttttatgcc tgaaaggcga tctcaccatg 120 ctgcaaacca ccatctgccg cctgaacggc gtggagtgcg aaagcccggt ggtgatttgc 180 aatgagcagc accgctttat tgtcgcggaa cagctgcgtc aactgaacaa acttaccgag 240 aacattattc tcgaaccggc agggcgaaac acggcacctg ccattgcgct ggcggcgctg 300 gcggcaaaac gtcatagccc ggagagcgac ccgttaatgc tggtattggc ggcggatcat 360 gtgattgccg atgaagacgc gttccgtgcc gccgtgcgta atgccatgcc atatgccgaa 420 gcgggcaagc tggtgacctt cggcattgtg ccggatctac cagaaaccgg ttatggctat 480 attcgtcgcg gtgaagtgtc tgcgggtgag caggatatgg tggcctttga agtggcgcag 540 tttgtcgaaa aaccgaatct ggaaaccgct caggcctatg tggcaagcgg cgaatattac 600 tggaacagcg gtatgttcct gttccgcgcc ggacgctatc tcgaagaact gaaaaaatat 660 cgcccggata tcctcgatgc ctgtgaaaaa gcgatgagcg ccgtcgatcc ggatctcaat 720 tttattcgcg tggatgaaga agcgtttctc gcctgcccgg aagagtcggt ggattacgcg 780 gtcatggaac gtacggcaga tgctgttgtg gtgccgatgg atgcgggctg gagcgatgtt 840 ggctcctggt cttcattatg ggagatcagc gcccacaccg ccgagggcaa cgtttgccac 900 ggcgatgtga ttaatcacaa aactgaaaac agctatgtgt atgctgaatc tggcctggtc 960 accaccgtcg gggtgaaaga tctggtagtg gtgcagacca aagatgcggt gctgattgcc 1020 gaccgtaacg cggtacagga tgtgaaaaaa gtggtcgagc agatcaaagc cgatggtcgc 1080 catgagcatc gggtgcatcg cgaagtgtat cgtccgtggg gcaaatatga ctctatcgac 1140 gcgggcgacc gctaccaggt gaaacgcatc accgtgaaac cgggcgaggg cttgtcggta 1200 cagatgcacc atcaccgcgc ggaacactgg gtggttgtcg cgggaacggc aaaagtcacc 1260 attgatggtg atatcaaact gcttggtgaa aacgagtcca tttatattcc gctgggggcg 1320 acgcattgcc tggaaaaccc ggggaaaatt ccgctcgatt taattgaagt gcgctccggc 1380 tcttatctcg aagaggatga tgtggtgcgt ttcgcggatc gctacggacg ggtgtaa 1437 <210> 12 <211> 1395 <212> DNA <213> Escherichia coli MG1655 <400> 12 tcaatatgcc gctttgttaa cgaaaccttt gaacaccgtc aggaaaacga ttttgatatc 60 gaaccagacg ctccattcgc ggatgtactc aaggtcgaac tcgacgcgtt tttccatttt 120 ctccagcgtg tcggtttcgc cgcgccagcc gttaatctgc gcccagccgg taatgcccgg 180 tttcacctta tggcgcagca tgtagccttc aatgagctgt cgatactgtt cgttatgcgc 240 tactgcgtgc ggacgtggac cgacaatcga catccccccg gtcagcacat tgataaactg 300 cggcaattca tccagcgagg tacggcgcag aaagttcccc actttggtga cgcgcggatc 360 gttctgcgtc gcctgggtca ccactttgtc gttctccatc actttcatgg aacggaactt 420 ccacactttg atcggcttgc catccatgcc gtagcgagtc tggcggaaaa taaccggccc 480 tggtgaactg agtttcaccg ccagcgcaat acagcacagc accggggaga tcagcagcag 540 aataagcgtc gccagcacaa tgtcttccgc acgtttgagc aggcggttaa ccccggaaag 600 cggcgtgtcg taaagcggca ccaccggtac gccgttcatc tcttcgaggc gtgaatggag 660 aatgttgaag gtaaagacgt cggggatcag cagcaccgaa caggtggtgt ccgccagttg 720 atggaccagt tttttcactc gcgcgccgtc gcacatttgc atcgcgatat agacgttatg 780 aatcttgccc gctttcgcgt cctcgaccag ctgttgcagg ttacccgccc agtcgttaga 840 aacgccgccc ggtttcgggt cgtggtaaac gcccaccact tcaaacccta accacggctg 900 gttacggaag ctctccatca gcatttgccc ggcggctaaa tcccccgcca ccgcgaccat 960 gcgcttgtta tagccatgat tacgcagcca gcccgcccca atgcgaatac acgaacggca 1020 aaccaccagt ccgatgctgg tcagcgcata ccacgccagc cagattttca gttgcgtgtc 1080 gaaatcattg ttgaacgcca ccagtccggc gctgaaaatc acgcttaagg tccagttttg 1140 tagcaacagg gcaaattctg tcgctgcccg aacaccgcgc catgagcgat aaaaatcggt 1200 gatgccgccc agcatctgga acaccaccag cgtaatcagc gccaccaaca ggtgcatgta 1260 gaggaatgac agtccgctga cttcgcaaac cagccatagt ccggcaaaca tgatggtgat 1320 atctgaaaag cgttgcacca tagagattaa cgatgcattg gttttcgctc gctcgcgctt 1380 ttttagattt gtcat 1395 <210> 13 <211> 660 <212> DNA <213> pEX18Gm plasmid <400> 13 atggagaaaa aaatcactgg atataccacc gttgatatat cccaatggca tcgtaaagaa 60 cattttgagg catttcagtc agttgctcaa tgtacctata accagaccgt tcagctggat 120 attacggcct ttttaaagac cgtaaagaaa aataagcaca agttttatcc ggcctttatt 180 cacattcttg cccgcctgat gaatgctcat ccggaattcc gtatggcaat gaaagacggt 240 gagctggtga tatgggatag tgttcaccct tgttacaccg ttttccatga gcaaactgaa 300 acgttttcat cgctctggag tgaataccac gacgatttcc ggcagtttct acacatatat 360 tcgcaagatg tggcgtgtta cggtgaaaac ctggcctatt tccctaaagg gtttattgag 420 aatatgtttt tcgtctcagc caatccctgg gtgagtttca ccagttttga tttaaacgtg 480 gccaatatgg acaacttctt cgcccccgtt ttcaccatgg gcaaatatta tacgcaaggc 540 gacaaggtgc tgatgccgct ggcgattcag gttcatcatg ccgtttgtga tggcttccat 600 gtcggcagaa tgcttaatga attacaacag tactgcgatg agtggcaggg cggggcgtaa 660 <210> 14 <211> 1422 <212> DNA <213> pEX18Gm plasmid <400> 14 atgaacatca aaaagtttgc aaaacaagca acagtattaa cctttactac cgcactgctg 60 gcaggaggcg caactcaagc gtttgcgaaa gaaacgaacc aaaagccata taaggaaaca 120 tacggcattt cccatattac acgccatgat atgctgcaaa tccctgaaca gcaaaaaaat 180 gaaaaatatc aagttcctga attcgattcg tccacaatta aaaatatctc ttctgcaaaa 240 ggcctggacg tttgggacag ctggccatta caaaacgctg acggcactgt cgcaaactat 300 cacggctacc acatcgtctt tgcattagcc ggagatccta aaaatgcgga tgacacatcg 360 atttacatgt tctatcaaaa agtcggcgaa acttctattg acagctggaa aaacgctggc 420 cgcgtcttta aagacagcga caaattcgat gcaaatgatt ctatcctaaa agaccaaaca 480 caagaatggt caggttcagc cacatttaca tctgacggaa aaatccgttt attctacact 540 gatttctccg gtaaacatta cggcaaacaa acactgacaa ctgcacaagt taacgtatca 600 gcatcagaca gctctttgaa catcaacggt gtagaggatt ataaatcaat ctttgacggt 660 gacggaaaaa cgtatcaaaa tgtacagcag ttcatcgatg aaggcaacta cagctcaggc 720 gacaaccata cgctgagaga tcctcactac gtagaagata aaggccacaa atacttagta 780 tttgaagcaa acactggaac tgaagatggc taccaaggcg aagaatcttt atttaacaaa 840 gcatactatg gcaaaagcac atcattcttc cgtcaagaaa gtcaaaaact tctgcaaagc 900 gataaaaaac gcacggctga gttagcaaac ggcgctctcg gtatgattga gctaaacgat 960 gattacacac tgaaaaaagt gatgaaaccg ctgattgcat ctaacacagt aacagatgaa 1020 attgaacgcg cgaacgtctt taaaatgaac ggcaaatggt acctgttcac tgactcccgc 1080 ggatcaaaaa tgacgattga cggcattacg tctaacgata tttacatgct tggttatgtt 1140 tctaattctt taactggccc atacaagccg ctgaacaaaa ctggccttgt gttaaaaatg 1200 gatcttgatc ctaacgatgt aacctttact tactcacact tcgctgtacc tcaagcgaaa 1260 ggaaacaatg tcgtgattac aagctatatg acaaacagag gattctacgc agacaaacaa 1320 tcaacgtttg cgccaagctt cctgctgaac atcaaaggca agaaaacatc tgttgtcaaa 1380 gacagcatcc ttgaacaagg acaattaaca gttaacaaat aa 1422 <210> 15 <211> 20 <212> DNA <213> pCAGO plasmid <400> 15 tagtccatcg aaccgaagta 20
Claims
1. A genetically engineered bacterium for producing 2′-fucosyllactose using mannose as a carbon source, wherein the genetically engineered bacterium is used to produce 2′-fucosyllactose, wherein: The engineering bacteria uses Escherichia coli as the starting strain, and knocks out lacI, lacZ Genes and overexpression wcaG, gmd, lacy Gene, then knocked out the gene encoding phosphomannose isomerase in the genome manA , overexpression of the gene encoding phosphomannose mutase manB , 2′-fucosyllactose synthase encoding gene futC , mannose-1-phosphate guanyltransferase encoding gene manC income; The method for preparing 2′-fucosyllactose by fermentation is as follows: the engineered bacteria seed solution is inoculated in a fermentation medium at a rate of 2-10%, at 30-37° C., 400-600 rpm, and cultured for 36-52 hours; The fermentation medium is composed of: 1.5-3.5 g / L KH2PO4, 1.5-3.5 g / L NH4Cl, 1.7-2.5 g / L citric acid, 1.4-2 g / L MgSO4·7H2O, 5-7 g / L yeast powder, 10-20 mL / L trace element solution, 1-10 g / L mannose, 10-15 g / L glycerol, 5-10 g / L lactose, and the rest is water.
2. The use according to claim 1, characterized in that use P trc Promoter overexpression wcaG, gmd, lacy Gene.
3. The use according to claim 1, characterized in that Expression using pSB4K5 plasmid futC、manC .
4. The use according to claim 1, characterized in that Expression using pTrc99a plasmid manb .
5. The use according to claim 1, characterized in that UDP-glucose lipid transporter gene was also knocked out W .
6. The use according to claim 1, characterized in that Escherichia coli MG1655 was used as the starting strain.
7. The use according to claim 1, characterized in that Said P lac Promoter, the nucleotide sequence of which is shown in SEQ ID NO: 1; Said lacI Gene, the nucleotide sequence is shown in SEQ ID NO:2; Said lacZ Gene, the nucleotide sequence is shown in SEQ ID NO:3; Said P trc Promoter, the nucleotide sequence of which is shown in SEQ ID NO:4; Said wxya Gene, the nucleotide sequence is shown in SEQ ID NO:5; Said gmd Gene, the nucleotide sequence is shown in SEQ ID NO:6; Said lacy Gene, the nucleotide sequence is shown in SEQ ID NO:7; Said manA Gene, the nucleotide sequence is shown in SEQ ID NO:8; Said manB Gene, the nucleotide sequence is shown in the sequence listing SEQ ID NO:9; Said futC Gene, the nucleotide sequence of which is shown in the sequence listing SEQ ID NO: 10; Said manC Gene, the nucleotide sequence of which is shown in SEQ ID NO:11; Said W The nucleotide sequence of the gene is shown in SEQ ID NO: 12.
Citation Information
Patent Citations
Method for synthesizing human milk fucosylation oligosaccharide by using genetic engineering strain through coupling and fermenting
CN102120999A
Genetically engineered bacterium for producing 2'-fucosyllactose and application of genetically engineered bacterium
CN112342176A
